Nautilus Biotechnology (Nautilus Biotechnology) Cash-to-Debt : 5.39 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Nautilus Biotechnology's cash to debt ratio for the quarter that ended in Mar. 2024 was 5.39.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Nautilus Biotechnology could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Nautilus Biotechnology's Cash-to-Debt or its related term are showing as below:

NAUT' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.48 Med: 8.85 Max: 543.94
Current: 5.39

During the past 4 years, Nautilus Biotechnology's highest Cash to Debt Ratio was 543.94. The lowest was 4.48. And the median was 8.85.

NAUT's Cash-to-Debt is ranked worse than
52.49% of 1526 companies
in the Biotechnology industry
Industry Median: 6.315 vs NAUT: 5.39

Nautilus Biotechnology Cash-to-Debt Historical Data

The historical data trend for Nautilus Biotechnology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Nautilus Biotechnology Cash-to-Debt Chart

Nautilus Biotechnology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

16.07

11.51

6.08

5.01

Nautilus Biotechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial											4.49	4.48	5.14	5.01	5.39

Competitive Comparison of Nautilus Biotechnology's Cash-to-Debt

For the Biotechnology subindustry, Nautilus Biotechnology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nautilus Biotechnology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's Cash-to-Debt falls into.

Nautilus Biotechnology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Nautilus Biotechnology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	173.418	/	(3.538	+	31.09)
	=	5.01

Nautilus Biotechnology's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	181.366	/	(3.675	+	29.946)
	=	5.39

Nautilus Biotechnology (NAS:NAUT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Nautilus Biotechnology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2701 Eastlake Avenue East, Seattle, WA, USA, 98102

Website

https://www.nautilus.bio

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

Executives

Michael Seth Altman	director	C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar	officer: Senior VP, Product Development	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld	officer: Chief People Officer	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry	officer: CFO and Treasurer	C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy	officer: General Counsel	C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel	director, 10 percent owner, officer: CEO, President, and Secretary	C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin	officer: Senior VP, Operations	3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya	director	SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	director	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain	director	1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz	10 percent owner	2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen	10 percent owner	C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111